- cafead Sep 11, 2020 at 12:12: PM
via With several new acute migraine treatments vying for market share, Eli Lilly is touting new data on Reyvow showing the med can provide patients “pain freedom” in as little as one hour, plus sustained relief for up to two days.
In a phase 3 trial called Centurion, patients who took Lilly’s new drug at the 200mg dose were 4.6 times more likely to experience pain freedom at the two-hour mark compared with those who took placebo.
article source
In a phase 3 trial called Centurion, patients who took Lilly’s new drug at the 200mg dose were 4.6 times more likely to experience pain freedom at the two-hour mark compared with those who took placebo.
article source